Results 131 to 140 of about 4,953,128 (334)
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology, EarlyView.The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source
Molecular Research in Medical Genetics. [PDF]
Int J Mol Sci, 2022 Viggiano E.
europepmc +1 more source
Methodology in Medical Genetics. An Introduction to Statistical Methods [PDF]
, 1977 P. S. Harper
openalex +1 more source
Molecular Oncology, EarlyView.Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner +6 more
wiley +1 more source
Editorial: Methods in cancer genetics
Frontiers in Oncology, 2023 Simona D’Aguanno, Pawel Buczkowicz
doaj +1 more source
Molecular Oncology, EarlyView.Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva +5 more
wiley +1 more source
Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). [PDF]
Genet Med Open, 2023 Scott AI +4 more
europepmc +1 more source